Ixekizumab— a new drug for the treatment of psoriasis, an anti-interleukin 17 monoclonal antibody
JIANG Wen-jing
ZHU Wei
Abstract：Psoriasis is a common, chronic inflammatory skin disease, manifested as red plaques with adherent silvery scales. The exact pathogenesis of psoriasis remains unclear, and interleukin-17(IL-17) is currently considered to play a critical role in it. Newly developed biological agents targeting the IL-17 pathway -Ixekizumab(IXE) has been used to treat psoriasis in clinical trials, which has been proved to be effective and safe in the treatment of psoriasis vulgaris and psoriatic arthritis. However, there is still a need for a long-term evaluation of IXE's safety.
Keywords：PsoriasisIL-17Biological agentsIXE
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 162-164 )